A new treatment for Dravet syndrome has slashed seizures by up to 91% in trials, giving hope to Nigerian families with few options.
TheDigger Intelligence Unit
An experimental drug has shown impressive results for children with Dravet syndrome, a rare and severe genetic type of epilepsy that affects families in Nigeria, where awareness and resources are limited.
In clinical trials, zorevunersen reduced seizures by up to 91% and improved quality of life.
Some AI-based analysis tools have attempted to interpret these scientific findings, but experts emphasise that such ‘AI detectors’ are designed to flag possible AI-generated text, not to evaluate the accuracy or importance of medical research.
They caution that these tools can give false positives, especially with technical or medical writing.
Results from these tools should not be considered authoritative or used as the basis for judging scientific breakthroughs.
The international study, led by University College London and Great Ormond Street Hospital, appeared in The New England Journal of Medicine.
Researchers found the drug to be safe and well-tolerated, and possibly helpful for some cognitive and behavioural symptoms of the disorder.
Dravet syndrome is a global concern that affects families across continents. While high-income countries have made progress in research and access to care, many low- and middle-income countries face huge disparities in diagnosis and treatment. International organisations, such as the World Health Organisation and Epilepsy Foundation, are working to improve epilepsy care worldwide, but access remains uneven.
Understanding Dravet Syndrome
Dravet syndrome is a rare type of epilepsy that starts in infancy and causes frequent, hard-to-control seizures.
It is caused by mutations in the SCN1A gene, which disrupts the brain’s electrical signaling.
Children often face other problems too, such as developmental delays, trouble moving, feeding issues, and a higher risk of early death.
Until now, therapies have mostly focused on controlling seizures, but with limited success. Current treatments rarely stop all seizures and do not help with these other challenges.
Targeting the Genetic Cause
Zorevunersen, made by Stoke Therapeutics and Biogen, targets the genetic cause of Dravet syndrome. In Nigeria, where genetic testing and treatment options are limited, such a drug could be especially significant.
The disorder is caused by a faulty SCN1A gene that produces insufficient levels of a protein needed for normal nerve signalling. The drug helps the healthy copy of the gene make more protein, aiming to restore normal brain function.
Breakthrough Clinical Outcomes
Eighty-one children joined the first UK and US trial and saw their seizures drop by up to 91% after treatment. Most side effects were mild.
Professor Helen Cross of UCL and Great Ormond Street Hospital said the results were promising: “This new treatment could help children with Dravet syndrome lead much healthier and happier lives.”
A pediatric neurologist in Lagos, commented: “While these results are exciting, we must ensure that Nigerian families can access genetic testing and specialist care. Otherwise, the benefits of innovation may not reach everyone who needs them.”
Hope and Challenges in Nigeria
Although the trial took place in Europe and the United States, this breakthrough is especially important for Nigerian doctors and families facing epilepsy.
In Nigeria, where treatment options are few and epilepsy is common, this news has raised hopes for better therapies that could help children in more ways than just controlling seizures.
Dravet Syndrome Nigeria, a patient advocacy group, noted that limited treatment options and stigma remain major challenges locally.
A representative called international research a beacon of hope and showed strong interest in making these promising trials available to Nigerian children with Dravet syndrome.
However, the path to access remains challenging. Regulatory approval will be required from Nigerian authorities, and there are questions about the drug’s cost and whether insurance or government programs will make it affordable.
Advocacy groups are campaigning for subsidies and inclusion in public health programs.
Real-Life Transformations
Freddie, eight, reduced from nightly seizures to just one or two short episodes every few days. His mother described the change as life-changing, saying Freddie now enjoys a life once thought impossible.
Next Steps for Global Access
A larger Phase 3 trial is now in progress to confirm how well the drug works and how safe it is. Researchers are also exploring new gene therapies and other innovative approaches for genetic epilepsies, hoping that success with zorevunersen may open the door to treatments for similar rare diseases.
The emergence of these new therapies also raises important ethical questions about access to experimental drugs, the use of placebo groups in trials, and the equitable distribution of these therapies worldwide.
Families and advocacy groups, including Dravet Syndrome Nigeria, say these early results offer much-needed hope for children in Nigeria living with Dravet syndrome, where new treatments could transform epilepsy care.